LVP Life Science Ventures
1
70M
1
1
- Areas of investment
Summary
The standard case for the fund is to invest in rounds with more than 10 partakers. Despite the LVP Life Science Ventures, startups are often financed by PathoCapital, OUP (Osage University Partners), Northwestern University. The meaningful sponsors for the fund in investment in the same round are Rock Springs Capital, PathoCapital, Partner Fund Management.
The top activity for fund was in 2017. The higher amount of exits for fund were in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 deals per year.
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical. Among the most popular portfolio startups of the fund, we may highlight Aptinyx.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Investments by industry
- Biotechnology (1)
- Health Care (1)
- Medical (1)
- Biopharma (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Aptinyx | 18 Dec 2017 | Biotechnology, Health Care, Medical, Biopharma | Early Stage Venture | 70M | United States, Illinois |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.